Madrigal

Madrigal Pharmaceuticals (MDGL)

Company Description

Madrigal Pharmaceuticals is developing novel, high-quality small-molecule drugs addressing major unmet needs in cardiovascular and metabolic diseases. The Company is targeting treatment of both niche and prevalent indications, including fatty liver disease and non-alcoholic steatohepatitis (NASH), diabetes, dyslipidemia and cardiovascular disease.

COMPANY ADDRESS
200 Barr Harbor Drive, Suite 400
West Conshohocken, PA 19428
United States

COMPANY EMAIL
info@madrigalpharma.com

COMPANY WEBSITE



Get BioInvest's perspective on Madrigal Pharmaceutical's CEO


Latest Company News

Breaking: Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) Stock Through Resistance ... CML News - Mar 16, 2017 Breaking: Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) has hit maximum technical strength -- watch the technical oscillators for momentum gaps. [...]
Thu, Mar 16, 2017 5:03:00 PM, Continue reading at the source
A New Kind of Stock Chart: Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) Critical ... CML News - Feb 27, 2017 This is a real time view of the critical technical pivot points for Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) . The technical pivot points we look at all surround the stock price movement from the last 10-trading days through the last year. [...]
Mon, Feb 27, 2017 3:11:00 AM, Continue reading at the source
Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) Stock Technicals Hit Weakness CML News - Feb 23, 2017 This is a technical analysis stock rating for Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) . The company has a two bull technical rating which indicates some weakness. [...]
Thu, Feb 23, 2017 3:56:00 PM, Continue reading at the source
Madrigal Pharmaceuticals Announces the Initiation of a Phase 2 Study of MGL ... GlobeNewswire (press release) - Feb 23, 2017 CONSHOHOCKEN, Pa., Feb. 23, 2017 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced that the first patient has been dosed in its Phase 2 study of MGL-3196 for the treatment of heterozygous familial ... [...]
Thu, Feb 23, 2017 1:07:00 PM, Continue reading at the source
Madrigal Pharmaceuticals Announces the Initiation of a Phase 2 Study of MGL ... GlobeNewswire (press release) - Oct 20, 2016 CONSHOHOCKEN, Pa., Oct. 20, 2016 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq:MDGL) today announced that the first patient has been dosed in its Phase 2 study of MGL-3196 for the treatment of non-alcoholic steatohepatitis (NASH). [...]
Thu, Oct 20, 2016 11:26:00 AM, Continue reading at the source
Madrigal Pharmaceuticals and Tarveda Therapeutics Announce Exclusive License ... GlobeNewswire (press release) - Sep 19, 2016 CONSHOHOCKEN, Pa. and WATERTOWN, Mass., Sept. 19, 2016 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) and Tarveda Therapeutics, Inc. today announced an exclusive worldwide license agreement providing for the ... With $163M Deal, Tarveda Revives Synta Pharma's Cancer Drug Work - Xconomy Tarveda to Develop Oncology Treatments Based on Madrigal's HSP90 Drug ... - Genetic Engineering & Biotechnology News (blog) [...]
Mon, Sep 19, 2016 11:26:00 AM, Continue reading at the source
Synta - Madrigal Merger: Is There A Potential Value Play Here? Seeking Alpha - Aug 23, 2016 On April 13, 2016 Synta and Madrigal Pharmaceuticals (NASDAQ:MDGL) entered into an arrangement and plan of merger pursuant to which Saffron Merger Sub Inc., a wholly owned subsidiary of Synta, will merge into MDGL, with Madrigal surviving as the ... [...]
Tue, Aug 23, 2016 11:48:00 PM, Continue reading at the source
Richard S. Levy, MD, Appointed to Madrigal Board of Directors GlobeNewswire (press release) - Aug 11, 2016 FORT WASHINGTON, Pa., Aug. 11, 2016 (GLOBE NEWSWIRE) -- MADRIGAL PHARMACEUTICALS, Inc. (Nasdaq:MDGL), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for ... [...]
Thu, Aug 11, 2016 11:26:00 AM, Continue reading at the source
Madrigal Pharmaceuticals Completes Merger with Synta to Create Leading ... GlobeNewswire (press release) - Jul 22, 2016 FORT WASHINGTON, Pa., July 22, 2016 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutic candidates for the ... [...]
Fri, Jul 22, 2016 3:22:00 PM, Continue reading at the source
Synta Stock Up on Merger Deal with Madrigal Pharmaceuticals Zacks.com - Apr 15, 2016 This all-stock transaction will lead to the formation of a new company named Madrigal Pharmaceuticals, which will focus on the development of novel small-molecule drugs addressing major unmet needs related to cardiovascular-metabolic diseases and ... Synta Pharma and Madrigal Pharma to merge in all-stock deal - Seeking Alpha Synta and Madrigal Announce Merger Agreement to Create Leading Cardiovascular ... - Business Wire (press release) [...]
Fri, Apr 15, 2016 2:47:00 PM, Continue reading at the source